GlaxoSmithKline
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of GlaxoSmithKline generated cash of $7,403,000,000, which is less than the previous year. Cash used in financing activities reached the amount of $823,000,000 last year. Net change in cash is therefore -$394,000,000.
Cash Flow
| 2013 | 7.22B | 524M | -6.27B |
|---|---|---|---|
| 2014 | 5.17B | -1.07B | -5.38B |
| 2015 | 2.56B | 6.03B | -7.10B |
| 2016 | 6.49B | -1.26B | -6.39B |
| 2017 | 6.91B | -1.44B | -6.38B |
| 2018 | 8.42B | -1.55B | -6.38B |
| 2019 | 8.02B | -5.35B | -1.84B |
| 2020 | 8.44B | 2.16B | -10.13B |
| 2021 | 7.95B | -1.77B | -7.58B |
| 2022 | 7.40B | -8.77B | 823M |
GSK.SW Cash Flow Statement (2013 – 2022)
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 3.81B | 5.26B | 4.83B | 4.08B | 3.6B | 4.60B | 5.48B | 4.02B | 5.23B | 3.90B |
Operating activities | ||||||||||
Net income | 4.92B | 4.38B | 5.74B | 4.64B | 3.62B | 1.53B | 912M | 8.42B | 2.75B | 5.43B |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 2.29B | 2.52B | 2.35B | 2.33B | 1.85B | 1.92B | 1.77B | 1.63B | 1.48B | 1.41B |
Stock-based compensation expense | 0 | 0 | 381M | 365M | 360M | 333M | 319M | 368M | 332M | 319M |
| Deferred income tax benefit | 0 | 0 | 381M | 365M | 360M | 333M | 319M | 368M | 332M | 319M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 119M | 300M | 51M | -461M | 70M | -111M | -529M | -95M |
Accounts payable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by operating activities | 7.40B | 7.95B | 8.44B | 8.02B | 8.42B | 6.91B | 6.49B | 2.56B | 5.17B | 7.22B |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | -1M | -258M | -309M | 4M | 809M | -2M | 1M | -133M |
Investments In Property Plant And Equipment | -2.25B | -2.93B | -2.23B | -2.16B | -1.79B | -2.20B | -2.35B | -1.90B | -1.75B | -1.70B |
Acquisitions Net | -3.13B | 185M | 3.00B | -3.78B | -292M | 356M | 592M | 7.52B | 235M | 1.95B |
Cash generated by investing activities | -8.77B | -1.77B | 2.16B | -5.35B | -1.55B | -1.44B | -1.26B | 6.03B | -1.07B | 524M |
Financing activities | ||||||||||
Common Stock Issued | 25M | 21M | 29M | 51M | 74M | 56M | 89M | 73M | 167M | 585M |
Payments for dividends | -3.46B | -3.99B | -3.97B | -3.95B | -3.92B | -3.90B | -4.85B | -3.87B | -3.84B | -3.68B |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | -65M | -74M | -99M | -333M | -1.54B |
Repayments of term debt | 0 | -1.99B | -7.30B | 0 | -2.06B | 0 | -919M | 0 | -1.70B | -1.87B |
Cash used in financing activities | 823M | -7.58B | -10.13B | -1.84B | -6.38B | -6.38B | -6.39B | -7.10B | -5.38B | -6.27B |
Net Change In Cash | -394M | -1.44B | 431M | 744M | 487M | -1.00B | -881M | 1.45B | -1.20B | 1.32B |
Cash at end of period | 3.42B | 3.81B | 5.26B | 4.83B | 4.08B | 3.6B | 4.60B | 5.48B | 4.02B | 5.23B |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |